Skip to content
2000
image of An Unusual Adverse Drug Reaction to Thalidomide: A Case Report

Abstract

Introduction

Thalidomide has emerged as a novel antitumor drug with antiangiogenic and immunomodulatory properties. It was taken off the market in the early 1960s due to its infamous connection with congenital defects. Recently, the FDA approved thalidomide for treating erythema nodosum leprosum, adhering to strict guidelines and safety measures. Sensory peripheral neuropathy and teratogenicity, fatigue, vertigo, headache, gastrointestinal issues, skin eruptions, dizziness, galactorrhoea, decreased libido, and constitutional symptoms like fever, weakness, headaches, and weight loss are the main adverse effects of thalidomide.

Case Report

We report a case of a 46-year-old female diagnosed with lepromatous leprosy on multibacillary multidrug therapy presenting with unusual adverse reactions, such as generalized burning sensation, breathlessness, and low backache after the intake of thalidomide.

Conclusion

We describe an unusual adverse reaction to thalidomide that has not previously been reported in the literature and aim to alert clinicians about the unusual, adverse reaction as an uncommon side effect of thalidomide and to always keep in mind if the patient develops any of these symptoms.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cds/10.2174/0115748863378453250623061903
2025-07-08
2025-10-06

  • From This Site

    /content/journals/cds/10.2174/0115748863378453250623061903
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Kim J.H. Scialli A.R. Thalidomide: The tragedy of birth defects and the effective treatment of disease. Toxicol. Sci. 2011 122 1 1 6 10.1093/toxsci/kfr088 21507989
    [Google Scholar]
  2. Andrews P.L.R. Williams R.S.B. Sanger G.J. Anti-emetic effects of thalidomide: Evidence, mechanism of action, and future directions. Curr. Res. Pharmacol. Drug Discov. 2022 3 100138 10.1016/j.crphar.2022.100138 36568268
    [Google Scholar]
  3. Franks M.E. Macpherson G.R. Figg W.D. Thalidomide. Lancet 2004 363 9423 1802 1811 10.1016/S0140‑6736(04)16308‑3 15172781
    [Google Scholar]
  4. Rehman W. Arfons L.M. Lazarus H.M. The rise, fall and subsequent triumph of thalidomide: Lessons learned in drug development. Ther. Adv. Hematol. 2011 2 5 291 308 10.1177/2040620711413165 23556097
    [Google Scholar]
  5. Ghobrial I.M. Rajkumar S.V. Management of thalidomide toxicity. J Support Oncol 2003 1 3 194 205
    [Google Scholar]
  6. Negera E. Walker S.L. Girma S. Doni S.N. Tsegaye D. Lambert S.M. Idriss M.H. Tsegay Y. Dockrell H.M. Aseffa A. Lockwood D.N. Clinico-pathological features of erythema nodosum leprosum: A case-control study at ALERT hospital, Ethiopia. PLoS Negl. Trop. Dis. 2017 11 10 0006011 10.1371/journal.pntd.0006011 29028793
    [Google Scholar]
  7. Kumar B. Dogra S. Kaur I. Epidemiological characteristics of leprosy reactions: 15 years experience from north India. Int. J. Lepr. Other Mycobact. Dis. 2004 72 2 125 133 10.1489/1544‑581X(2004)072<0125:ECOLRY>2.0.CO;2 15301592
    [Google Scholar]
  8. Pocaterra L. Jain S. Reddy R. Muzaffarullah S. Torres O. Suneetha S. Lockwood D.N.J. Clinical course of erythema nodosum leprosum: An 11-year cohort study in Hyderabad, India. Am. J. Trop. Med. Hyg. 2006 74 5 868 879 10.4269/ajtmh.2006.74.868 16687695
    [Google Scholar]
  9. Van Veen N.H.J. Lockwood D.N.J. van Brakel W.H. Ramirez J. Jr Richardus J.H. Interventions for erythema nodosum leprosum. Cochrane Libr. 2009 2012 10 CD006949 10.1002/14651858.CD006949.pub2 19588412
    [Google Scholar]
  10. Walker S.L. Lebas E. Doni S.N. Lockwood D.N.J. Lambert S.M. The mortality associated with erythema nodosum leprosum in Ethiopia: a retrospective hospital-based study. PLoS Negl. Trop. Dis. 2014 8 3 2690 10.1371/journal.pntd.0002690 24625394
    [Google Scholar]
  11. Elliott M.A. Mesa R.A. Li C.Y. Hook C.C. Ansell S.M. Levitt R.M. Geyer S.M. Tefferi A. Thalidomide treatment in myelofibrosis with myeloid metaplasia. Br. J. Haematol. 2002 117 2 288 296 10.1046/j.1365‑2141.2002.03443.x 11972510
    [Google Scholar]
  12. Treon S.P. Soumerai J.D. Branagan A.R. Hunter Z.R. Patterson C.J. Ioakimidis L. Briccetti F.M. Pasmantier M. Zimbler H. Cooper R.B. Moore M. Hill J. II Rauch A. Garbo L. Chu L. Chua C. Nantel S.H. Lovett D.R. Boedeker H. Sonneborn H. Howard J. Musto P. Ciccarelli B.T. Hatjiharissi E. Anderson K.C. Thalidomide and rituximab in Waldenstrom macroglobulinemia. Blood 2008 112 12 4452 4457 10.1182/blood‑2008‑04‑150854 18713945
    [Google Scholar]
  13. Thomas D.A. Giles F.J. Albitar M. Cortes J.E. Verstovsek S. Faderl S. O’Brien S.M. Garcia-Manero G. Keating M.J. Pierce S. Zeldis J. Kantarjian H.M. Thalidomide therapy for myelofibrosis with myeloid metaplasia. Cancer 2006 106 9 1974 1984 10.1002/cncr.21827 16583431
    [Google Scholar]
  14. Wu J.J. Huang D.B. Pang K.R. Hsu S. Tyring S.K. Thalidomide: Dermatological indications, mechanisms of action and side-effects. Br. J. Dermatol. 2005 153 2 254 273 10.1111/j.1365‑2133.2005.06747.x 16086735
    [Google Scholar]
  15. Naranjo C.A. Busto U. Sellers E.M. Sandor P. Ruiz I. Roberts E.A. Janecek E. Domecq C. Greenblatt D.J. A method for estimating the probability of adverse drug reactions. Clin. Pharmacol. Ther. 1981 30 2 239 245 10.1038/clpt.1981.154 7249508
    [Google Scholar]
  16. Aate J. Management of adverse drug reactions: A review. IP Int. J. Compr. Adv. Pharmacol. 2024 9 1 45 51 10.18231/j.ijcaap.2024.007
    [Google Scholar]
  17. Edwards I.R. Aronson J.K. Adverse drug reactions: Definitions, diagnosis, and management. Lancet 2000 356 9237 1255 1259 10.1016/S0140‑6736(00)02799‑9 11072960
    [Google Scholar]
/content/journals/cds/10.2174/0115748863378453250623061903
Loading
An Unusual Adverse Drug Reaction to Thalidomide: A Case Report
Bentham Science Publishers ; https://doi.org/10.2174/0115748863378453250623061903
/content/journals/cds/10.2174/0115748863378453250623061903
/content/journals/cds/10.2174/0115748863378453250623061903
Loading

Data & Media loading...


  • Article Type:     Case Report
Keywords: leprosy ; multibacillary multidrug therapy ; erythema nodosum leprosum ; unusual reaction ; adverse drug reactions ; Thalidomide

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test